O Gara et al 2013 ACCF/AHA STEMI Guideline e415 513. Orsinelli DA, Pearson AC. Usefulness of transesophageal echocardiog- raphy to screen for left atrial thrombus before elective cardioversion for atrial fibrillation. Am J Cardiol. 1993;72:1337 9. 514. Wall TC, Califf RM, Harrelson-Woodlief L, et al; the TAMI Study Group. Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. Am J Cardiol. 1990;66:1418 21. 515. Patel MR, Meine TJ, Lindblad L, et al. Cardiac tamponade in the fibrino- lytic era: analysis of >100,000 patients with ST-segment elevation myo- cardial infarction. Am Heart J. 2006;151:316 22. 516. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26:549 57. 517. Gueret P, Khalife K, Jobic Y, et al. Echocardiographic assessment of the incidence of mechanical complications during the early phase of myo- cardial infarction in the reperfusion era: a French multicentre prospective registry. Arch Cardiovasc Dis. 2008;101:41 7. 518. L pez-Send n J, Gurfinkel EP, Lopez de Sa E, et al. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31:1449 56. 519. Figueras J, Juncal A, Carballo J, et al. Nature and progression of pericar- dial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture. Am Heart J. 2002;144:251 8. 520. Figueras J, Barrab s JA, Serra V, et al. Hospital outcome of moderate to severe pericardial effusion complicating ST-elevation acute myocardial infarction. Circulation. 2010;122:1902 9. 521. Andreotti F, Testa L, Biondi-Zoccai GGL, et al. Aspirin plus warfa- rin compared to aspirin alone after acute coronary syndromes: an up- dated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519 26. 522. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Prac- tice Guidelines. Chest. 2012;141:e531S e575S. 523. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary preven- tion of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e637S 68S. Erra- tum in: Chest. 2012;141:1129. 524. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/ or undergoing coronary stenting: executive summary: a Consensus Docu- ment of the European Society of Cardiology Working Group on Throm- bosis. Eur Heart J. 2010;31:1311 8. 525. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: an- tithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North-American perspective. Thromb Haemost. 2011;106:572 84. 526. Turpie AGG, Chin BSP, Lip GYH. Venous thromboembolism: patho- physiology, clinical features, and prevention. BMJ. 2002;325:887 90. 527. Ng TMH, Tsai F, Khatri N, et al. Venous thromboembolism in hospi- talized patients with heart failure: incidence, prognosis, and prevention. Circ Heart Fail. 2010;3:165 73. 528. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis compar- ing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing fre- quency. Arch Intern Med. 2000;160:181 8. 529. Matsuo T, Tomaru T, Kario K, et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute cor- onary syndrome. Thromb Res. 2005;115:475 81. 530. Ohman EM, Granger CB, Rice L, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a reg- istry of prolonged heparin use and thrombocytopenia among hospital- ized patients with and without cardiovascular disease: the Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. J Thromb Thrombolysis. 2005;19:11 9. 531. Crespo EM, Oliveira GBF, Honeycutt EF, et al. Evaluation and manage- ment of thrombocytopenia and suspected heparin-induced thrombocyto- penia in hospitalized patients: the ComplicationsAfterThrombocytopenia Caused by Heparin (CATCH) Registry. Am Heart J. 2009;157:651 7. 532. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with war- farin. Am J Med. 1998;105:91 9. 533. S rensen R, Hansen ML,Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospec- tive analysis of nationwide registry data. Lancet. 2009;374:1967 74. arin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e495S e530S. 535. Rao SV, O Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200 6. 536. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocar- dial infarction? Circulation. 2007;116:2793 801. 537. Giugliano RP, Giraldez RR, Morrow DA, et al. Relations between bleed- ing and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010;31:2103 10. 538. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocar- dial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532 9. Erratum in: JAMA. 2008;299:2390. 539. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfu- sion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555 62. 540. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and compli- cations after cardiac surgery. N Engl J Med. 2008;358:1229 39. 541. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction under- going primary angioplasty: results from the HORIZONS-AMI (Harmo- nizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2009;54:1438 46. 542. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned gly- coprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853 63. Erratum in: JAMA. 2003;289:1638. 543. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108 16. Erratum in: JAMA. 2006;295:628. 544. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleed- ing on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774 82. 545. Rao SV, O Grady K, Pieper KS, et al. A comparison of the clinical im- pact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809 16. 546. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362 8. 547. Mathews R, Peterson ED, Chen AY, et al. In-hospital major bleeding dur- ing ST-elevation and non-ST-elevation myocardial infarction care: deri- vation and validation of a model from the ACTION Registry-GWTG. Am J Cardiol. 2011;107:1136 43. 548. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients under- going percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Car- diovasc Interv. 2009;2:222 9. 549. Kadakia MB, Desai NR, Alexander KP, et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry-GWTG (National Cardio- vascular Data Registry Acute Coronary Treatment and Intervention Out- comes Network Registry Get With the Guidelines). JACC Cardiovasc Interv. 2010;3:1166 77. 550. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarc- tion 38 (TRITON-TIMI 38). Circulation. 2011;123:2681 9. 551. H bert PC, Wells G, Blajchman MA, et al; Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A mul- ticenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409 17. Erratum in: N Engl J Med. 1999;340:1056. 552. Aronson D, Dann EJ, Bonstein L, et al. Impact of red blood cell transfu- sion on clinical outcomes in patients with acute myocardial infarction. Am J Cardiol. 2008;102:115 9. 553. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleed- ing in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556 66. 554. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:257S 98S. 555. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombi- nant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127 37. 556. Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol. 2008;65:1313 8. 557. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing per- cutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936 45. 558. Rao SV, Ou F-S, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardio- vasc Interv. 2008;1:379 86. 559. Agostoni P, Biondi-Zoccai GGL, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interven- tional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44:349 56. 560. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial ac- cess site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94:1019 25. 561. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coro- nary angiography and intervention in patients with acute coronary syn- dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409 20. Errata in: Lancet. 2011;377:1408 and Lancet. 2011;378:30. 562. Patel MR, Jneid H, Derdeyn CP, et al. Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association. Circulation. 2010;122:1882 93. Erratum in: Circula- tion. 2010;122:e507. 563. Marso SP, Amin AP, House JA, et al. Association between use of bleed- ing avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303:2156 64. 564. Koreny M, Riedm ller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac cathe- terization: systematic review and meta-analysis. JAMA. 2004;291:350 7. 565. Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complica- tions after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv. 2008;1:202 9. 566. Dauerman HL, Rao SV, Resnic FS, et al. Bleeding avoidance strategies: consensus and controversy. J Am Coll Cardiol. 2011;58:1 10. 567. Kosiborod M, McGuire DK. Glucose-lowering targets for patients with cardiovascular disease: focus on inpatient management of patients with acute coronary syndromes. Circulation. 2010;122:2736 44. 568. Pinto DS, Skolnick AH, Kirtane AJ, et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment eleva- tion myocardial infarction. J Am Coll Cardiol. 2005;46:178 80. 569. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in pa- tients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018 27. 570. Finfer S, Chittock DR, Su SY-S, et al. Intensive versus conventional glu- cose control in critically ill patients. N Engl J Med. 2009;360:1283 97. 571. Mehta SR,Yusuf S, D az R, et al. Effect of glucose-insulin-potassium in- fusion on mortality in patients with acute ST-segment elevation myocar- dial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437 46. 572. van der Horst ICC, Zijlstra F, van t Hof AWJ, et al. Glucose-insulin- potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a random- ized trial. J Am Coll Cardiol. 2003;42:784 91. 573. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administra- tion of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925 33. 574. Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med. 2000;342:749 55. 575. Newby LK, Hasselblad V, Armstrong PW, et al. Time-based risk assess- ment after myocardial infarction: implications for timing of discharge and applications to medical decision-making. Eur Heart J. 2003;24:182 9. 576. Antman EM, Kuntz KM. The length of the hospital stay after myocardial infarction. N Engl J Med. 2000;342:808 10. 577. Th roux P, Waters DD, Halphen C, et al. Prognostic value of exercise testing soon after myocardial infarction. N Engl J Med. 1979;301:341 5. 578. Villella A, Maggioni AP, Villella M, et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with throm- bolytic agents: the GISSI-2 data-base: Gruppo Italiano per lo Studio della Sopravvivenza Nell Infarto. Lancet. 1995;346:523 9. 579. Leppo JA, O Brien J, Rothendler JA, et al. Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after acute myo- cardial infarction. N Engl J Med. 1984;310:1014 8. 580. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac ra- dionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the Ameri- can Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Car- diovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation. 2009;119:e561 87. 581. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/ HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, So- ciety of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2011;57:1126 66. 582. Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010 up- date: performance measures on cardiac rehabilitation for referral to cardiac rehabilitation/secondary prevention services. Circulation. 2010;122:1342 50. 583. Jain A, Myers GH, Sapin PM, et al. Comparison of symptom-limited and low level exercise tolerance tests early after myocardial infarction. J Am Coll Cardiol. 1993;22:1816 20. 584. Roffi M, Wenaweser P, Windecker S, et al. Early exercise after coronary stenting is safe. J Am Coll Cardiol. 2003;42:1569 73. 585. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Prac- tice Guidelines (Committee to Update the 1997 Exercise Testing Guide- lines). Circulation. 2003;107:149 58. Erratum in: J Am Coll Cardiol. 2006;48:1731. 586. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: executive summary: a report of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108:1404 18. 587. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implant- able cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481 8. 588. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427 36. 589. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defi- brillator in patients with myocardial infarction and reduced ejection frac- tion. N Engl J Med. 2002;346:877 83. 590. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. Erratum in: N Engl J Med. 2005;352:2146. 591. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Im- plantation Trial II. Circulation. 2010;122:1265 71. O Gara et al 2013 ACCF/AHA STEMI Guideline e417 592. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Founda- tion/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2012;126:1784-1800. Erratum in: Circulation. 2013;127:e357 9. 593. Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial. Ann Intern Med. 1994;120:999 1006. 594. Coleman EA, Parry C, Chalmers S, et al. The care transitions interven- tion: results of a randomized controlled trial. Arch Intern Med. 2006; 166:1822 8. 595. Young W, Rewa G, Goodman SG, et al. Evaluation of a community- based inner-city disease management program for postmyocardial infarc- tion patients: a randomized controlled trial. CMAJ. 2003;169:905 10. 596. Jack BW, Chetty VK,Anthony D, et al.A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150:178 87. 597. Lapp JM, Muhlestein JB, Lapp DL, et al. Improvements in 1-year car- diovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med. 2004;141:446 53. 598. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and sec- ondary prevention of coronary heart disease: an American Heart As- sociation scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcom- mittee on Physical Activity), in collaboration with the American Asso- ciation of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111:369 76. Erratum in: Circulation. 2005;111:1717. 599. Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54:25 33. 600. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analy- sis of randomized controlled trials. Am J Med. 2004;116:682 92. 601. Goel K, Lennon RJ, Tilbury RT, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary inter- vention in the community. Circulation. 2011;123:2344 52. 602. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mor- tality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000;160:939 44. 603. Thomson CC, Rigotti NA. Hospital- and clinic-based smoking cessation interventions for smokers with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:459 79. 604. Dawood N, Vaccarino V, Reid KJ, et al. Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med. 2008;168:1961 7. 605. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, re- current myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010;106:911 6. 606. Bernheim SM, Grady JN, Lin Z, et al. National patterns of risk-stan- dardized mortality and readmission for acute myocardial infarction and heart failure: update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3:459 67. 607. Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc. 2003;51:549 55. 608. Coleman EA, Boult C. Improving the quality of transitional care for per- sons with complex care needs. J Am Geriatr Soc. 2003;51:556 7. 609. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient s perspective: the care transitions measure. Med Care. 2005;43:246 55. 610. Bernheim SM, Spertus JA, Reid KJ, et al. Socioeconomic disparities in outcomes after acute myocardial infarction.Am Heart J. 2007;153:313 9. 611. RahimiAR, Spertus JA, Reid KJ, et al. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA. 2007;297:1063 72. 612. Smolderen KG, Spertus JA, Reid KJ, et al. The association of cogni- tive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009;2:328 37. 613. Kaiser Permanente. Case Study: Collaborative Cardiac Care Service Collaborative Teams Improve Cardiac Care with Health Information Technology. March 27, 2009. Available at: http://xnet.kp.org/future/ ahrstudy/032709cardiac.html. Accessed March 10, 2011. 614. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Re- habilitation, and Prevention Committee, the Council on Clinical Car- diology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007;115:2675 82. 615. Suaya JA, Shepard DS, Normand S-LT, et al. Use of cardiac rehabilita- tion by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation. 2007;116:1653 62. 616. Snow V, Beck D, Budnitz T, et al. Transitions of care consensus policy statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society- American College of Emergency Physicians-Society of Academic Emer- gency Medicine. J Gen Intern Med. 2009;24:971 6. 617. National Quality Forum. Safe Practices for Healthcare 2010 update. Available at: http://qualityforum.org/projects/safe_practices_2010.aspx. Accessed December 9, 2010. 618. The Joint Commission. 2010 National Patient Safety Goals. Available at: http://www.jointcommission.org/standards_information/npsgs.aspx. Accessed December 9, 2010. 619. National Quality Forum. Preferred practices and performance measures for measuring and reporting care coordination. Available at: http:// qualityforum.org/projects/care_coordination.aspx. Accessed December 9, 2010. 620. Desai MM, Stauffer BD, Feringa HHH, et al. Statistical models and pa- tient predictors of readmission for acute myocardial infarction: a system- atic review. Circ Cardiovasc Qual Outcomes. 2009;2:500 7. 621. Verouden NJW, Haeck JDE, Kuijt WJ, et al. Prediction of 1-year mortal- ity with different measures of ST-segment recovery in all-comers after primary percutaneous coronary intervention for acute myocardial infarc- tion. Circ Cardiovasc Qual Outcomes. 2010;3:522 9. 622. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of pa- tients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. November 20. doi:10.1161/ CIR.0b013e318277d6a0. Available at: http://circ.ahajournals.org/look- up/doi/10/1161/CIR.0b013e318277d6a0. Accessed November 20, 2012. 623. American College of Chest Physicians. Tobacco Cessation Toolkit. Available at: http://tobaccodependence.chestnet.org/. Accessed March 9, 2011. 624. Deleted in press. 625. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560 72. Erratum in: JAMA. 2003;290:197. 626. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardio- vascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Asso- ciation. Diabetes Care. 2007;30:162 72. 627. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incor- porated into the ACC/AHA 2005 guidelines for the diagnosis and man- agement of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Prac- tice Guidelines, developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391 479. Erratum in: Circulation. 2010;121:e258. 627a Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardio- vascular disease: a scientific statement from the American Heart Associa- tion. Circulation. 2012;125:1058 72 628. Mosca L,Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for car- diovascular disease prevention in women. Circulation. 2004;109:672 93. 629. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Pre- vention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2008;118:1768 75. 630. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of in- fluenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1 40. 631. Curry LA, Spatz E, Cherlin E, et al. What distinguishes top-performing hospitals in acute myocardial infarction mortality rates? A qualitative study. Ann Intern Med. 2011;154:384 90. 632. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial in- farction. JAMA. 2010;303:2148 55. 633. STREAM (Strategic Reperfusion [With Tenecteplase and Antithrombot- ic Treatment] Early After Myocardial Infarction) Trial. 2011. ClinicalTri- als.gov identifier: NCT00623623. Available at: http://clinicaltrials.gov/ ct2/show/NCT00623623. Accessed November 1, 2010. 634. McLean S, Wild S, Connor P, et al. Treating ST elevation myocardial infarction by primary percutaneous coronary intervention, in-hospital thrombolysis and prehospital thrombolysis: an observational study of timelines and outcomes in 625 patients. Emerg Med J. 2011;28:230 6. 635. Blankenship JC, Scott TD, Skelding KA, et al. Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST- segment elevation myocardial infarction percutaneous coronary interven- tion in a rural setting. J Am Coll Cardiol. 2011;57:272 9. 636. Flynn A, Moscucci M, Share D, et al. Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction un- dergoing primary percutaneous coronary intervention. Arch Intern Med. 2010;170:1842 9. 637. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312 9. 638. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9 19. 639. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vora- paxar in acute coronary syndromes. N Engl J Med. 2012;366:20 33. 640. Bekkers SCAM, Yazdani SK, Virmani R, et al. Microvascular obstruc- tion: underlying pathophysiology and clinical diagnosis. J Am Coll Car- diol. 2010;55:1649 60. 641. Timmers L, Henriques JPS, de Kleijn DPV, et al. Exenatide reduces in- farct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501 10. 642. Wu KC. Fighting the fire of myocardial reperfusion injury: how to de- fine success? J Am Coll Cardiol. 2009;53:730 1. 643. Deleted in press. 644. Prasad A, Stone GW, Holmes DR, et al. Reperfusion injury, microvas- cular dysfunction, and cardioprotection: the dark side of reperfusion. Circulation. 2009;120:2105 12. 645. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pre- treatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Cir- culation. 2011;123:1622 32. 646. Dorian P, Hohnloser SH, Thorpe KE, et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortal- ity in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). Cir- culation. 2010;122:2645 52. 647. Terzic A, Nelson TJ. Regenerative medicine advancing health care 2020. J Am Coll Cardiol. 2010;55:2254 7. 648. Sch chinger V, Erbs S, Els sser A, et al. Intracoronary bone marrow- derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210 21. 649. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32:1736 47. 650. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mono- nucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J. 2011; 32:1748 57. 651. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110 9. 652. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere- derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895 904. 653. Ptaszek LM, Mansour M, Ruskin JN, et al. Towards regenerative therapy for cardiac disease. Lancet. 2012;379:933 42. 654. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-de- rived stem-cell transfer in patients with ST-segment elevation myo- cardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113 21. 655. Dill T, Sch chinger V, Rolf A, et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in pa- tients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (RE- PAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J. 2009;157:541 7. 656. Bolli R, Chugh AR, D Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847 57. Key Words: AHA Scientific Statements anticoagulants antiplatelets door-to-balloon fibrinolysis percutaneous coronary intervention reperfusion ST-elevation myocardial infarction thrombolysis O Gara et al 2013 ACCF/AHA STEMI Guideline e419 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Patrick T. O Gara, Chair Harvard Medical School Professor of Medicine None None None None None None None Frederick G. Kushner, Vice Chair Tulane University School of Medicine Clinical Professor of Medicine; Heart Clinic of Louisiana Medical Director None None None None Novartis None 8.1 Deborah D. Ascheim Mount Sinai School of Medicine Associate Professor; InCHOIR Clinical Director of Research None None None None None None None Donald E. Casey, Jr. Atlantic Health Chief Medical Officer and Vice President of Quality None None None None None None None Mina K. Chung Cleveland Clinic Foundation Associate Professor of Medicine Biotronik Boston Scientific Nexcura PGx Sanofi-aventis St. Jude Medical None None Biotronik Boston Scientific GlaxoSmith Kline Medtronic Siemens Medical Solutions St. Jude Medical ZOLL Medtronic Boston Scientific St. Jude Medical None None James A. de Lemos UT Southwestern Medical School Professor of Medicine Johnson & Johnson Tethys AstraZeneca Daiichi-Sankyo BMS/ Sanofi- aventis None Bristol-Myers Squibb (DSMB) Roche Merck/Schering-Plough Daiichi-Sankyo None None 4.4.1 Steven M. Ettinger Penn State Heart & Vascular Institute Professor of Medicine and Radiology None None None Medtronic None None 4.3.1 James C. Fang University Hospitals Case Medical Center Director, Heart Transplantation Accorda Novartis Thoratec None None None Medtronic None 9.5.4.1 Francis M. Fesmire Heart Stroke Center Director Abbott None None None None Plaintiff, Missed Barry A. Franklin William Beaumont Hospital Director, Cardiac Rehabilitation and Exercise Laboratories None None None None None None None Christopher B. Granger Duke Clinical Research Institute Director, Cardiac Care Unit; Assistant Professor of Medicine AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline Hoffman La Roche Novartis Sanofi-aventis The Medicines Company None None Astellas AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb Eli Lilly GlaxoSmithKline Medtronic Merck Sanofi-aventis The Medicines Company None None 4.4.1 (Continued) Appendix 1. Continued Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Harlan M. Krumholz Yale University School of Medicine Professor of Medicine United HealthCare (Science Advisory Group) None None None None None None Jane A. Linderbaum Mayo Clinic Assistant Professor of Medicine None None None None None None None David A. Morrow Harvard Medical School Associate Professor of Medicine Beckman-Coulter Boehringer Ingelheim Daiichi-Sankyo Eli Lilly Genentech Merck Novartis OrthoClinical Diagnostics/Johnson & Johnson Roche Diagnostics Sanofi-aventis Schering-Plough Research Institute Siemens Medical Solutions None None AstraZeneca Beckman-Coulter Daiichi-Sankyo Eli Lilly GlaxoSmithKline Merck Nanosphere Novartis Roche Diagnostics Sanofi-aventis Schering-Plough Research Institute Siemens Medical Solutions Singulex AstraZeneca None 3.2 L. Kristin Newby Duke University Medical Center, Division of Cardiology Professor of Medicine Amgen AstraZeneca BioVascular Johnson & Johnson Novartis None None BG Medicine Bristol-Myers Squibb diaDexus Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Regado Schering-Plough None None 4.4.1 Joseph P. Ornato Department of Emergency Medicine Virginia Commonwealth University Professor and Chairman European Resuscitation Council ZOLL Circulation None None NIH/NINDS Neurological Emergency Treatment Trials Consortium PI None None None Narith Ou Mayo Clinic Pharmacotherapy Coordinator, Cardiology None None None None None None None Martha J. Radford NYU Langone Medical Center Chief Quality Officer; NYU School of Medicine Professor of Medicine (Cardiology) None None None None None None None Jacqueline E. Tamis-Holland St Luke s-Roosevelt Hospital Center Director, Interventional Cardiology Fellowship Program; Columbia University, College of Physicians and Surgeons Assistant Professor of Clinical Medicine None None None None None None None (Continued) O Gara et al 2013 ACCF/AHA STEMI Guideline e421 Appendix 1. Continued Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Carl L. Tommaso Skokie Hospital Director of Catheterization Laboratory; North Shore University Health Systems None None None None None None None Cynthia M. Tracy George Washington University Medical Center Associate Director, Division of Cardiology None None None None None None None Y. Joseph Woo Hospital of the University of Pennsylvania Associate Professor of Surgery None None None None None None None David X. Zhao Vanderbilt University Medical Center Director, Cardiac Catheterization and Interventional Cardiology None None None Abbot Vascular Accumetrics AGA Medical Osiris Volcano None None 4.3.1 This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document. *Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities could apply. No financial benefit. Significant relationship. Dr. Ettinger s relationship with Medtronic was added just before balloting of the recommendations, so it was not relevant during the writing stage; however, the addition of this relationship makes the writing committee out of compliance with the minimum 50% no relevant RWI requirement. ACS indicates acute coronary syndromes; DSMB, data safety monitoring board; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; and PI, principal investigator. Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Elliott M. Antman Official Reviewer ACCF Board of Trustees None None None Accumetrics AstraZeneca Beckman Coulter Bristol-Myers Squibb Pharmaceutical Research Institute Daiichi-Sankyo* Eli Lilly* GlaxoSmithKline Merck Millennium Pharmaceuticals Novartis Pharmaceuticals Ortho-Clinical Diagnostics Sanofi-Synthelabo Recherche Schering-Plough Research Institute None None Gary J. Balady Official Reviewer AHA None None None None None None Christopher P. Cannon Official Reviewer AHA Novartis None None Accumetrics* AstraZeneca* Bristol-Myers Squibb GlaxoSmithKline Merck* GlaxoSmithKline Merck (DSMB) None Judith S. Hochman Official Reviewer ACCF/AHA Task Force on Practice Guidelines BMS/Sanofi Eli Lilly GlaxoSmithKline None None None Johnson & Johnson Pharmaceutical Research & Development (DSMB) Merck/Schering Plough (DSMB) None Austin H. Kutscher Official Reviewer ACCF Board of Governors None None None None None None Charles J. Davidson Organizational Reviewer SCAI Abbott* Abbott Vascular None None Edwards Lifesciences* None None Deborah B. Diercks Organizational Reviewer ACEP Abbott Cardiovascular Daiichi-Sankyo None None Beckman Coulter Nanosphere None None Jonathan M. Tobis Organizational Reviewer SCAI None AGA Medical None AGA Medical* None None Boston Scientific Jeffrey L. Anderson Content Reviewer ACCF/AHA Task Force on Practice Guidelines None None None Toshiba AstraZeneca (DSMB) Defendant, Postoperative Ablation Case, James C. Blankenship Content Reviewer None None None AstraZeneca Boston Scientific Novartis Schering-Plough None None Jeffrey J. Cavendish Content Reviewer ACCF Prevention of Cardiovascular Disease Committee None None None None None None Harold L. Dauerman Content Reviewer None None None None None None John S. Douglas, Jr. Content Reviewer None None None Abbott Medtronic The Medicines Company None None Stephen G. Ellis Content Reviewer Abbott Vascular Boston Scientific None None None None None (Continued) O Gara et al 2013 ACCF/AHA STEMI Guideline e423 Appendix 2. Continued Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Joseph Fredi Content Reviewer ACCF Surgeons Scientific Council AGA Medical None None None None None Anthony Gershlick Content Reviewer Abbott AstraZeneca Boehringer Ingelheim Boston Scientific Cordis Eli Lilly Medtronic None None Boehringer Ingelheim None None Howard C. Herrmann Content Reviewer AstraZeneca Merck Sharpe and Dohme None None Accumetrics Boston Scientific* Edwards Lifesciences* eValve Medtronic* St. Jude Medical The Medicines Company* None None James Bernard Hermiller Content Reviewer ACCF Interventional Scientific Council Abbott Boston Scientific St. Jude Medical Eli Lilly None None None None Fred M. Kosumoto Content Reviewer None None None None None None Glenn Levine Content Reviewer None None None None None None Roxana Mehran Content Reviewer Abbott Vascular AstraZeneca Ortho-McNeill None None BMS/Sanofi-aventis* The Medicines Company* None None M. Eugene Sherman Content Reviewer ACCF Board of Governors None Eli Lilly* None None None None Daniel I. Simon Content Reviewer Cordis/Johnson & Johnson Daiichi-Sankyo Eli Lilly Medtronic Sanofi-aventis The Medicines Company None None None None Defendant, DES Intellectual Property Case, Richard W. Smalling Content Reviewer ACCF Interventional Scientific Council AGA Medical None None AGA Medical* Cordis* eValve* AGA Medical Cordis eValve None William G. Stevenson Content Reviewer ACCF/AHA Task Force on Practice Guidelines None None None None None None William A. Tansey III Content Reviewer None None None None None None David D. Waters Content Reviewer Bristol-Myers Squibb Pfizer None None None Merck/Schering-Plough Sanofi-aventis (DSMB) None Christopher J. White Content Reviewer None None None Boston Scientific St. Jude Medical None None (Continued) Appendix 2. Continued Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Clyde W. Yancy Content Reviewer ACCF/AHA Task Force on Practice Guidelines None None None None None None Yerem Yeghiazarians Content Reviewer None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document. *Significant relationship. No financial benefit. ACCF indicates American College of Cardiology Foundation; ACEP, American College of Emergency Physicians; AHA, American Heart Association; DES, drug-eluting stent; DSMB, data safety monitoring board; and SCAI, Society for Cardiovascular Angiography and Interventions. O Gara et al 2013 ACCF/AHA STEMI Guideline e425 Appendix 3. Abbreviation List ACE = angiotensin-converting enzyme ACS = acute coronary syndrome AF = atrial fibrillation ARB = angiotensin receptor blocker AV = atrioventricular BMS = bare-metal stent BP = blood pressure CABG = coronary artery bypass graft COX-2 = cyclooxygenase-II enzyme CPR = cardiopulmonary resuscitation CrCl = creatinine clearance D2B = door-to-balloon (device) DAPT = dual antiplatelet therapy DES = drug-eluting stent ECG = electrocardiogram/electrocardiographic ED = emergency department EF = ejection fraction EMS = emergency medical services FMC = first medical contact GP = glycoprotein HF = heart failure HIT = heparin-induced thrombocytopenia IABP = intra-aortic balloon counterpulsation ICD = implantable cardioverter-defibrillator ICH = intracranial hemorrhage LBBB = left bundle-branch block LDL = low-density lipoprotein LV = left ventricular LVEF = left ventricular ejection fraction MI = myocardial infarction NRMI = National Registry of Myocardial Infarction PCI = percutaneous coronary intervention RCT = randomized controlled trial RV = right ventricular SCD = sudden cardiac death STEMI = ST-elevation myocardial infarction TIMI = Thrombolysis In Myocardial Infarction UFH = unfractionated heparin VF = ventricular fibrillation VT = ventricular tachycardia